Story preview
Continue reading on the publisher site for the full article.
Read on publisher →Yahoo Finance Singapore
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
5
in the last 3 days
First reported
3 days ago
4 outlets since
Countries
4 other outlets reported this story in the last 3 days.
Find the latest Bristol-Myers Squibb Co (BRMD.XD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Bristol-Myers Squibb recently secured an expanded U.S. FDA approval for CAMZYOS for symptomatic obstructive hypertrophic cardiomyopathy across adults and eligible pediatric patients, and also reported Phase 3 EXCALIBER-RRMM data showing higher MRD negative complete response rates for ZENBEXUS based triplet therapy in…
Bristol-Myers Squibb is a Hold as replacing lost revenue from Eliquis and Opdivo presents a significant challenge. Click here to read this BMY stock update.